# US 2013/0210884 A1 · Methods for Identifying Analgesic Agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0210884 A1
- Document ID: US20130210884A1
- Status: Published application
- Kind: A1
- Application number: 13/860,810
- Filed: 2013-04-11
- Published: 2013-08-15
- Earliest claimed: 2002-02-19
- Assignees: Xenon Pharmaceutical Inc.
- Inventors: Marcia MacDonald; Mark Samuels; Robin Sherrington; Yigal Paul Goldberg
- Web page: https://patentgrep.com/patent/US20130210884A1

## CPC

- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6897: involving reporter genes operably linked to promoters
- A01N 43/38: condensed with carbocyclic rings
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- C07H 21/04: with deoxyribosyl as saccharide radical
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/156: Polymorphic or mutational markers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.

## Claims

### Claim 1

A method of treating pain in a patient having a gain of function nucleotide polymorphism in an SCN9A gene, comprising administering to said patient a sodium channel blocking agent that selectively inhibits SCN9A polypeptide.

### Claim 2 (depends on 1)

The method of claim 1, wherein said gain of function polymorphism results in an SCN9A polypeptide having a tryptophan at amino acid 1150.

### Claim 3 (depends on 1)

The method of claim 1, wherein said sodium channel blocking agent is compound A.

### Claim 4 (depends on 1)

The method of claim 1, wherein said SCN9A gene without said polymorphism has the nucleotide sequence of SEQ ID NO: 3.

### Claim 5 (depends on 1)

The method of claim 1, wherein said SCN9A polypeptide has the amino acid sequence of SEQ ID NO: 2.

### Claim 6

A method of predicting the analgesic effect of a sodium channel blocking agent that selectively inhibits SCN9A polypeptide in a mammal, comprising:
(a) determining in said mammal the presence of a gain of function polymorphismin an SCN9A gene of said mammal,
(b) administering to said mammal an effective amount of Compound A, and
(c) determining a positive analgesic effect in said mammal due to said administering of step (b),
wherein said positive analgesic effect in step (c) indicates a positive analgesic effect by said sodium channel blocking agent.

### Claim 7 (depends on 6)

The method of claim 6, wherein said gain of function polymorphism results in an SCN9A polypeptide having a tryptophan at amino acid 1150.

### Claim 8 (depends on 6)

The method of claim 6, wherein said sodium channel blocking agent is an analog of compound A.

### Claim 9 (depends on 6)

The method of claim 6, wherein said SCN9A gene without said polymorphism has the nucleotide sequence of SEQ ID NO: 3.

### Claim 10 (depends on 6)

The method of claim 6, wherein said SCN9A polypeptide has the amino acid sequence of SEQ ID NO: 2.

### Claim 11 (depends on 6)

The method of claim 6, wherein said mammal is a human being.
